|
Alzheimer's Disease
|
0.050 |
Biomarker
|
disease |
BEFREE |
These data provide evidence for extremely rare apoptotic neuronal death in AD and PSP compatible with the progression of neuronal degeneration in these chronic diseases.
|
11205141 |
2000 |
|
PNEUMOTHORAX, PRIMARY SPONTANEOUS
|
0.040 |
Biomarker
|
disease |
BEFREE |
Primary spontaneous pneumothorax (PSP) generally occurs in young adults, whereas pediatric PSP is uncommon.
|
30955098 |
2019 |
|
PNEUMOTHORAX, PRIMARY SPONTANEOUS
|
0.040 |
Biomarker
|
disease |
BEFREE |
Further studies on earlier stage non-demented PSP patients are required to ascertain whether stereotypies are characteristic of PSP in general or are confined to PSP-RS, and whether they may be used to suggest a PSP diagnosis early in disease course.
|
30399478 |
2018 |
|
PNEUMOTHORAX, PRIMARY SPONTANEOUS
|
0.040 |
Biomarker
|
disease |
BEFREE |
We define a five-level theoretical construct for the utility of neuroimaging biomarkers in PSP, with level 1 representing group-level findings, level 2 representing biomarkers with demonstrable individual-level diagnostic utility, level 3 representing biomarkers for early disease, level 4 representing surrogate biomarkers of PSP pathology, and level 5 representing definitive PSP biomarkers of PSP pathology.
|
28500751 |
2017 |
|
PNEUMOTHORAX, PRIMARY SPONTANEOUS
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Rs186977284 was also present in 2.7% of a large cohort of autopsy-confirmed PSP patients (N = 566) and only 0.9% of an additional control series (P = 0.034, OR = 3.08), extending the association to PSP.
|
24121548 |
2014 |
|
Dry Eye Syndromes
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the Penn SICCA cohort, SP-1 IgM and PSP IgA autoantibodies were more prevalent in the serum of SS-related dry eye participants compared with those without SS.
|
31517725 |
2019 |
|
Pick Disease of the Brain
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
<b>Objectives:</b> The present study is geared to learning about the patterns of tau seeding and cells involved following unilateral inoculation in the corpus callosum of homogenates from sporadic Alzheimer's disease (AD), primary age-related tauopathy (PART: neuronal 4Rtau and 3Rtau), pure aging-related tau astrogliopathy (ARTAG: astroglial 4Rtau with thorn-shaped astrocytes TSAs), globular glial tauopathy (GGT: 4Rtau with neuronal tau and specific tau inclusions in astrocytes and oligodendrocytes, GAIs and GOIs, respectively), progressive supranuclear palsy (PSP: 4Rtau with neuronal inclusions, tufted astrocytes and coiled bodies), Pick's disease (PiD: 3Rtau with characteristic Pick bodies in neurons and tau containing fibrillar astrocytes), and frontotemporal lobar degeneration linked to P301L mutation (FTLD-P301L: 4Rtau familial tauopathy).
|
31191295 |
2019 |
|
Dryness of eye
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In the Penn SICCA cohort, SP-1 IgM and PSP IgA autoantibodies were more prevalent in the serum of SS-related dry eye participants compared with those without SS.
|
31517725 |
2019 |
|
Dry Eye Syndromes
|
0.030 |
Biomarker
|
disease |
BEFREE |
To investigate the value of 3 novel autoantibodies [salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP)] in differentiating Sjögren's syndrome (SS)-related dry eye from non-SS dry eye.
|
29504954 |
2018 |
|
Dry Eye Syndromes
|
0.030 |
Biomarker
|
disease |
BEFREE |
To evaluate the prevalence of novel candidate Sjogren syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment and Management (DREAM) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye.
|
30161055 |
2018 |
|
Dryness of eye
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
To investigate the value of 3 novel autoantibodies [salivary protein 1 (SP1), carbonic anhydrase 6 (CA6), and parotid secretory protein (PSP)] in differentiating Sjögren's syndrome (SS)-related dry eye from non-SS dry eye.
|
29504954 |
2018 |
|
Dryness of eye
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
To evaluate the prevalence of novel candidate Sjogren syndrome (SS) autoantibodies [salivary protein-1 (SP-1), parotid secretory protein, carbonic anhydrase 6] in the DRy Eye Assessment and Management (DREAM) cohort, a study evaluating the effectiveness of omega-3 fatty acid supplements for the treatment of dry eye.
|
30161055 |
2018 |
|
Frontotemporal dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Atrophy colocated with cerebellar areas implicated for motor (PSP, MSA) or cognitive symptoms (FTD, ALS, PSP) in the diseases.
|
28501823 |
2017 |
|
Corticobasal degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
We enrolled 34 de novo PD patients and 29 patients affected by atypical parkinsonisms (Multiple System Atrophy, MSA, n = 10; Progressive Supranuclear Palsy, PSP, n = 12 and Corticobasal Degeneration, CBD, n = 7) who underwent an acute levodopa challenge.
|
28207803 |
2017 |
|
Pick Disease of the Brain
|
0.030 |
Biomarker
|
disease |
BEFREE |
Over two dozen mutations in the gene encoding the microtubule associated protein tau cause a variety of neurodegenerative dementias known as tauopathies, including frontotemporal dementia (FTD), PSP, CBD and Pick's disease.
|
24086739 |
2013 |
|
Frontotemporal dementia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Frontotemporal dementia (FTD) refers to a disease spectrum including the behavioral variant FTD (bvFTD), primary progressive aphasia (PPA), progressive supranuclear palsy/corticobasal degeneration syndrome (PSP/CBDS), and FTD with amyotrophic lateral sclerosis (FTD-ALS).
|
23254636 |
2013 |
|
Frontotemporal dementia
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Over two dozen mutations in the gene encoding the microtubule associated protein tau cause a variety of neurodegenerative dementias known as tauopathies, including frontotemporal dementia (FTD), PSP, CBD and Pick's disease.
|
24086739 |
2013 |
|
Pick Disease of the Brain
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
|
Corticobasal degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
Further immunohistochemical and biochemical studies revealed that AgD is a four-repeat (4R) tauopathy similar to PSP and corticobasal degeneration (CBD), but distinct from Alzheimer's disease (AD) and Pick's disease.
|
15641585 |
2004 |
|
Corticobasal degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
Some of the sporadic disorders (progressive supranuclear palsy [PSP] and corticobasal degeneration) have been referred to by molecular pathologists as primary tauopathies, implicating abnormalities of tau in their pathogenesis.
|
14502653 |
2003 |
|
Diabetes
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
PSP/reg levels are elevated in cell culture and mouse models of Wolfram syndrome, a prototype of ER stress-induced diabetes.
|
30914711 |
2019 |
|
Diabetes Mellitus
|
0.020 |
AlteredExpression
|
group |
BEFREE |
PSP/reg levels are elevated in cell culture and mouse models of Wolfram syndrome, a prototype of ER stress-induced diabetes.
|
30914711 |
2019 |
|
nervous system disorder
|
0.020 |
Biomarker
|
group |
BEFREE |
The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy.
|
30726566 |
2019 |
|
Bradykinesia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Subsequently, the diagnosis was changed to PSP due to hypometric downward gaze, reduced blink frequency, symmetric bradykinesia, rigidity, and the absence of autonomic dysfunction.
|
31216016 |
2019 |
|
Ptosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The PSP was run by a Steering Group of three women with experience of pessary use, three experienced clinicians involved with management of prolapse, two researchers with relevant experience, a JLA adviser and a PSP leader.
|
29705767 |
2018 |